2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
51
Small Cell Lung Carcinoma
23
Breast Neoplasms
18
Sarcoma
17
Lung Neoplasms
10
Carcinoma, Hepatocellular
10
Esophageal Squamous Cell Carcinoma
9
Stomach Neoplasms
8
Neoplasms
8
Triple Negative Breast Neoplasms
7
Ovarian Neoplasms
7
Nasopharyngeal Carcinoma
7
Thyroid Neoplasms
6
Neoplasm Metastasis
6
Esophageal Neoplasms
6
Pancreatic Neoplasms
5
NSCLC
5
Colorectal Neoplasms
5
Carcinoma
5
Uterine Cervical Neoplasms
4
Pheochromocytoma
4
Endometrial Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Ovarian Epithelial
4
Recurrence
3
Paraganglioma
3
Non-squamous Non-small Cell Lung Cancer
3
Glioma
3
Fallopian Tube Neoplasms
3
Cholangiocarcinoma
3
Interventions
niraparib
2
olaparib
1
anlotinib
1
Trabectedin
1
Ocoxin
1
Laparoscopy
1
Diffusion
1
Dexamethasone
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adnexal Diseases
×
anlotinib
×
Clear all
NCT04566952
2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
68 enrolled